Key facts

Below are highlights of our performance over the last 12 months:

February 2017

$3m milestone received following achievement of a clinical milestone from collaboration with Corvus

March 2017

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

April 2017

FDA issues CRL on CCP-07 NDA

April 2017

$2m milestone received following successful completion of drug discovery collaboration

April 2017

€2m payment received following achievement of three milestones in oncology drug discovery collaboration with Servier

August 2017

FDA issues CRL on CCP-08 NDA

December 2017

€1m milestone payment received following achievement in third oncology collaboration with Servier

December 2017

New drug discovery research collaboration with Daiichi Sankyo

February 2018

Trading and Corporate Update

March 2018

Update on Strategic Review, Formal Sales Process and Directorate Changes

June 2018

Termination of Tris Agreement and update on Formal Sales Process

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch